Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:8 Number:530 ISSN#:2563-5476
ACE Report #3604
Ace Report Cover General Orthopaedics

Alendronate is superior to alfacalcidol in preventing glucocorticoid-induced bone loss

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis

N Engl J Med. 2006 Aug 17;355(7):675-84

Contributing Authors: RN de Nijs JW Jacobs WF Lems RF Laan A Algra AM Huisman E Buskens CE de Laet AC Oostveen PP Geusens GA Bruyn BA Dijkmans JW Bijlsma STOP Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


201 patients with a rheumatic disease who were starting daily doses of glucocorticoids were randomized to receive 10 mg of alendronate and a placebo capsule of alfacalcidol daily or 1 ug of alfacalcidol and a placebo tablet of alendronate daily. At 18 months, the lumbar spine bone mineral density of patients who received alendronate had increased significantly more than that of the patients who re...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.